La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?

Size: px
Start display at page:

Download "La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente?"

Transcription

1 La ricerca clinica farmacologica nel paziente anziano: un costo inutile o un dato assente? 57 Congresso Nazionale SIGG Società Italiana di Gerontologia e Geriatria Dr. Marco Scatigna Direttore Medico e Direttore Scientifico Sanofi Italia Direttore Generale Fondazione Sanofi-Aventis

2 2

3 3

4 4

5 Product Development A Risky and Expensive Proposition 5

6 Ranking by ethical drug sales 1981 Vs HOECHST BAYER MERCK & Co CIBA-GEIGY PFIZER AHP ROCHE SANDOZ LILLY ABBOTT WARNER LAMBERT UPJOHN BRISTOL SQUIBB 2009 PFIZER SANOFI-AVENTIS GLAXO SMITH KLINE NOVARTIS ROCHE ASTRAZENECA MERCK & Co JOHNSON & JOHNSON LILLY BOEHRINGER INGELHEIM ABBOTT BRISTOL-MYERS-SQUIBB TAKEDA BAYER 6

7 $ (in years) External Estimates of COST/NME Year of Estimate Sources: Tufts Center for Drug, Development, Boston Consulting Group, Lehman Brothers 7

8 Mean percentage TRENDS IN BREAKDOWN OF R&D EXPENDITURE BY ACTIVITY FOR MAJOR COMPANIES Discovery Non-clinical Total clinical Regulatory Other Source: IMS Health, Market Prognosis

9 Probability of being launched Attrition data (probability of success) All respondents (=29) Major (n=9) Medium (n=8) Other (n=12) Decision to start preclinical development Start of Phase I Start of Phase II Latest stage reached Start of Phase III Submission of dossier Source: CMR International 9

10 The Patient dilemma 10

11 The randomized controlled clinical trial

12 Historical barriers to the inclusion of elderly subjects in clinical trials Heterogeneity of health status (multiple comorbidities) Polypharmacy Pathophysiologic differences Cognitive function status (compliance, accettable informed consent, greater toxicity*) Logistic N.K.Wenger. Am J, Ger. Card Vol 15, N 6 *M. Markman. Oncology 2007, 72,

13 The imperfection 13

14 Excessive drop out 14

15 Only 22 to 36% of patients 65 years of age or older participate in trials for cancer therapy, even though they represent nearly 60% of the population with cancer Hutchins LF at al. New England Journal of Medicine 1999; 341:

16 Analysis of data from cancer patients in 55 trials between 1995 and 2002 found an enrolment rate of 9% among the over 75s, despite this age group represents 31% of the US cancer population Talarico L, Chen G, Pardur R. Journal of Clinical Oncology 2004;22:

17 Barrier Solution Participation Quality and calibre of the person doing the recruiting Informed consent Simple, short and comprehensive Access Issues Ethnic barriers Provide transportation, engage family members Bicultural approaches, engage family members Subject fear/concern Clear comunication of trials rules Gate keeper Influence Enlisting his cooperation good comunicator Comorbidity and Mortality Sample size adjusted for these different effects stratification 17

18 The HYpertension in the Very Elderly Trial ClinicalTrials.gov: NCT

19 Work Package 1. Literature review Andrew Beswick, Margaret Burke, Yoav Ben Shlomo and Paul Dieppe Medical Research Council Department of Social Medicine, University of Bristol Nuffield Department of Orthopaedic Surgery, University of Oxford November 2008 Increasing the participation of elderly in clinical trials Supported by the European Union, FP7 health research, grant number HEALTH-F

20 The leading pharmaceutical companies are losing between 14% and 41% of their existing revenues as a result of patent expires Company Share of Revenues (%) AstraZeneca Arimidex ($2.2bn)* Seroquel ($4.7bn) Symbicort ($3.7bn) BMS US Plavix ($4.8bn) Abilify ($2.1bn) Avapro ($1.3bn) GSK Advair ($3.8bn)* Avandia ($2.5bn) Eli Lilly Zyprexa ($4.8bn) Merck Cozaar/ ($3.2bn) Singulair ($4.5bn) Hyzaar Novartis Femara ($1.1bn)* Diovan ($6.0bn) Pfizer Aricept ($800m) Lipitor ($12.1bn) Viagra ($4.5bn) Xalatan ($1.6bn) Detrol ($860m) Geodon ($1.1bn) Sanofiaventis Taxotere ($2bn) US Plavix Avapro ($3.8bn) ($2.1bn) US Lovenox ($3.1bn) 38** Source: AXA Framlington 20

21 21

22 FDA Action to increase the number of clinical trials performed in children 1997 Modernization act 2002 BPCA (Best Pharmaceuticals for Children Act) 2003 PRIA (Pediatric Research Improvement Act) 2007 Amendments Act 22

23 As of March 2001, 181 drugs have received pediaric exclusivity under BPCA* pediatric studies have been completed involving patients**. *FDA. Pediatric Esclusivity Granted. March 2011 ** FDA. Breakdown of FDAAA Compleed Pediatric Studies 23

24 24

UK Pharma The UK Challenges

UK Pharma The UK Challenges UK Pharma The UK Challenges Malcolm Skingle CBE DSc PhD Director Academic Liaison Drug Discovery 15 th October 2012 Franco-British Bilateral Symposium on clinical research The Royal Society The Challenges

More information

Global Pharmaceutical Industry Facts at a glance

Global Pharmaceutical Industry Facts at a glance World market value and share In 2006, global pharmaceutical sales totalled US$643 billion with growth of 7% from the previous year. 1 Global pharmaceutical sales 2006 700 600 $559 billion $601 billion

More information

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry

Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is

More information

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies

The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies The Global Biotech Industry: Challenges & Opportunities Michael S. Rosen Rosen Bioscience Strategies Greetings from Chicago! Beaches Yes! Pharma Beginnings! Bogota 1974 Selling Drugs in Colombia Global

More information

CHEM-E4140 Selectivity 12. Pharma Business

CHEM-E4140 Selectivity 12. Pharma Business CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25

More information

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines

Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines Trends in the pharmaceutical industry and potential impact on future innovation and access to medicines The R&D Process: Long, Complex, and Costly Average cost of R&D is $1.2 Billion The Current Challenge

More information

The Practice of Pharmacovigilance in Pharmaceutical Industry DR. SIAN NG PRESIDENT, THE HKAPI 4 TH MARCH 2011

The Practice of Pharmacovigilance in Pharmaceutical Industry DR. SIAN NG PRESIDENT, THE HKAPI 4 TH MARCH 2011 The Practice of Pharmacovigilance in Pharmaceutical Industry 1 DR. SIAN NG PRESIDENT, THE HKAPI 4 TH MARCH 2011 HKAPI Hong Kong Association of Pharmaceutical Industry Formed in 1968; Membership 38 full

More information

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany

Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Careers in the Pharmaceutical Industry - what really counts - Dr. Wolfgang Haupt Novartis Vaccines & Diagnostics, Marburg, Germany Agenda Section 1 Overview on the Top Ten Pharmaceutical Companies Section

More information

Industry Book of Knowledge Practical Considerations for ectd Submissions: US IND Applications in ectd format: A CMC Perspective

Industry Book of Knowledge Practical Considerations for ectd Submissions: US IND Applications in ectd format: A CMC Perspective Industry Book of Knowledge Practical Considerations for ectd Submissions: US IND Applications in ectd format: A CMC Perspective A compilation of points to consider based on collective experiences from:

More information

November Clinical Trials in Poland Key Challenges

November Clinical Trials in Poland Key Challenges November 2010 Clinical Trials in Poland Key Challenges Table of Contents 1. Summary 1 2. Introduction: A global view 7 3. Clinical trials in Poland: Key characteristics 25 4. Benefits and risks of clinical

More information

Trends and Issues: Integrating Clinical Research in China with Global Development Programs

Trends and Issues: Integrating Clinical Research in China with Global Development Programs Trends and Issues: Integrating Clinical Research in China with Global Development Programs Bruce N. Garrett, MD President and CEO Global Research Services, LLC Global Medical Consulting Services (Shanghai)

More information

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global

Blockbuster!!! Content Management in the Pharmaceutical Industry An Overview. Global Pharma Market Shares by Sales (Approx. USD 700 Billion) Global Content Management in the Pharmaceutical Industry An Overview Blockbuster!!! Avatar USD 2 Billion revenues Lipitor USD 12.5 Billion in 2008 Dr Arun Gangatkar http://in.linkedin.com/in/drarungangatkar drarunj@gmail.com

More information

PRESCRIPTION DRUGS: BACKGROUND AND BASICS

PRESCRIPTION DRUGS: BACKGROUND AND BASICS PRESCRIPTION DRUGS: BACKGROUND AND BASICS Medicare & Medicaid Briefings National Health Policy Forum January 30, 2009 Jim Hahn Congressional Research Service PRESCRIPTION DRUGS FAQS What is the price of

More information

Introduction to the Pharmaceutical Industry

Introduction to the Pharmaceutical Industry Introduction to the Pharmaceutical Industry University Joins Industry March 11, 2015 Javier Torrejón Topics to be covered today.. History Drug$ Economics R&D. The core of the Industry RISK Factors Current

More information

2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK

2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK 2011 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK JUNE 2011 CMR OVERVIEW CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For close

More information

Water for pharmaceuticals Opportunities in the developed and emerging markets. Sample. $714.1m. Water for pharmaceuticals (2014)

Water for pharmaceuticals Opportunities in the developed and emerging markets. Sample. $714.1m. Water for pharmaceuticals (2014) Analysts report Water for pharmaceuticals Opportunities in the developed and emerging markets Executive summary Current status The severity of the patent cliff has ravaged the pharmaceutical industry.

More information

Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012

Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012 Primer: The Pharmaceutical Industry Han Zhong l Updated June 2012 Introduction The pharmaceutical industry produces prescription and over-the-counter drugs as well as biologic products primarily intended

More information

Direct-To-Consumer (DTC) Advertising in Pharmaceuticals - Global Strategic Business Report

Direct-To-Consumer (DTC) Advertising in Pharmaceuticals - Global Strategic Business Report Brochure More information from http://www.researchandmarkets.com/reports/1946808/ Direct-To-Consumer (DTC) Advertising in Pharmaceuticals - Global Strategic Business Report Description: This report analyzes

More information

MULTI PRODUCT BULK DRUG (API) PROJECT

MULTI PRODUCT BULK DRUG (API) PROJECT MULTI PRODUCT BULK DRUG (API) PROJECT At present the global Pharma market is estimated at US$ 500 billion. The market is expected to continue to grow at the rate of 5 to 6% per year. During the last decade

More information

- The need for sales force effectiveness for pharmaceutical companies and the factors that affect it.

- The need for sales force effectiveness for pharmaceutical companies and the factors that affect it. Brochure More information from http://www.researchandmarkets.com/reports/2204703/ Sales Force Effectiveness in Pharmaceuticals - Targeted Sales Models such as Enhanced Key Account Management (KAM) and

More information

MENA and East Europe Pharmaceutical Markets & Regulations. 1 Buenos Aires ETIF MENA & East Europe Regulations G. Rossi 2010 rev. 1.

MENA and East Europe Pharmaceutical Markets & Regulations. 1 Buenos Aires ETIF MENA & East Europe Regulations G. Rossi 2010 rev. 1. MENA and East Europe Pharmaceutical Markets & Regulations 1 Buenos Aires ETIF 2010 - MENA & East Europe Regulations G. Rossi 2010 rev. 1.0 1. Pharma Market Evolution 2. Potential Market Analysis: a. Focus

More information

PatientView About our series on Corporate Reputation of the Healthcare Industry from a Patient perspective

PatientView About our series on Corporate Reputation of the Healthcare Industry from a Patient perspective PatientView 2016 About our series on Corporate Reputation of the Healthcare Industry from a Patient perspective 2015-2016 1 PatientView 2016 DEFINITION: WHAT IS A PATIENT GROUP? PatientView s definition

More information

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30

CHAPTER FOUR: CLINICAL TRIAL COST AND FUNDING... 30 CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 INTENDED AUDIENCE... 2 METHODOLOGY... 2 ANALYST CREDENTIALS... 2 SCOPE OF REPORT... 2 INFORMATION SOURCES...

More information

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015

e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 e-labeling : innovation for patient or regulation nightmare Pharmapack Feb, 11 th, 2015 PHARMAPACK 2015 1 Mobile health x2 30 months 100 000 mapps Source: research2guidance, mhealth App Market Report 2013-2017

More information

A good presentation is like a dress; long enough to cover everything and short enough to keep your interest. Edith Vanderbilt

A good presentation is like a dress; long enough to cover everything and short enough to keep your interest. Edith Vanderbilt CERTAIN STATEMENTS IN THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO STATEMENTS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS OF FUTURE TRENDS AND OF OUR ANTICIPATED FUTURE PERFORMANCE, CONSTITUTE FORWARD-LOOKING

More information

TRANSPARENCY CODE of the INFARMA Employers Union of Innovative Pharmaceutical Companies

TRANSPARENCY CODE of the INFARMA Employers Union of Innovative Pharmaceutical Companies TRANSPARENCY CODE of the INFARMA Employers Union of Innovative Pharmaceutical Companies TRANSPARENCY CODE TRANSPARENCY CODE of the INFARMA Employers Union of Innovative Pharmaceutical Companies Preamble

More information

Fees From Transactions. (Includes Contributions, Sponsorships and Grants)

Fees From Transactions. (Includes Contributions, Sponsorships and Grants) Abbott Laboratories, Abbott Diabetes Care 101,806 920 68,686 141,916 Sub Total $ 171,412 $ 141,916 Total $ 313,328 AbbVie 50,889 21,170 Sub Total $ 72,059 Total $ 72,059 AstraZeneca 130,550 6,670 Pathway

More information

Innovative Drug R&D in China (Second Edition) New Developments and Future Prospects

Innovative Drug R&D in China (Second Edition) New Developments and Future Prospects 中国新国新药研发最新进展及前景分析 Innovative Drug R&D in China (Second Edition) New Developments and Future Prospects JZMed, Inc. Report Description Largely due to the constant cultivation and support of the Chinese government

More information

Basic facts about the EU pharma market

Basic facts about the EU pharma market Basic facts about the EU pharma market I. Market volume 1 Distribution of turnover for prescription medicines by originator companies in 2007 for USA, EU and Rest of the world Health spending across EU

More information

Global Pharmaceuticals Marketing Channel Reference EDITION

Global Pharmaceuticals Marketing Channel Reference EDITION Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry

More information

Supply Chain Process Monitoring & Analyzing with ARIS PPM

Supply Chain Process Monitoring & Analyzing with ARIS PPM Supply Chain Process Monitoring & Analyzing with ARIS PPM Fast discovery approach on european wide supply chain process monitoring Jörg Kösterke European Supply Chain Management Business Processes & Projects

More information

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th

Pharmaceutical sales in Canada have a 2.5 percent share of the global market, making th Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries

More information

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015

Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Brochure More information from http://www.researchandmarkets.com/reports/3398017/ Small-Cell Lung Cancer Global Clinical Trials Review, H2, 2015 Description: Small-Cell Lung Cancer Global Clinical Trials

More information

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final

EFPIA Position Paper on REACH. Executive Summary. Position Paper. Draft Final. Author: EFPIA Date: October 2015 Version: Final Draft Final EFPIA Position Paper on REACH Author: EFPIA Date: October 2015 Version: Final Position Paper Executive Summary An increasing number of substances used in the pharmaceutical manufacturing process

More information

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry

Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Shifting paths of pharmaceutical innovation: Implications for the global pharmaceutical industry Tariq Sadat PhD Candidate School of Economics, Finance and Marketing, RMIT University, Australia Roslyn

More information

DIACEUTICS PHARMA READINESS FOR PERSONALIZED MEDICINE SUMMARY REPORT Prepared using the Diaceutics Method

DIACEUTICS PHARMA READINESS FOR PERSONALIZED MEDICINE SUMMARY REPORT Prepared using the Diaceutics Method DIACEUTICS PHARMA READINESS FOR PERSONALIZED MEDICINE SUMMARY REPORT 2016 KEY TAKEAWAYS FROM THIS YEAR S REPORT Diaceutics Pharma Readiness for Personalized Medicine (PM) Benchmark Report is a quantitative

More information

Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor

Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Sharing Industry Clinical Trial Data: Improving Public Health While Maintaining the Oversight Relationship Between Regulator and Sponsor Steven Snapinn SCT/QSPI/FDA Workshop Innovations in the Science

More information

THE BIOTECH & PHARMACEUTICAL INDUSTRY

THE BIOTECH & PHARMACEUTICAL INDUSTRY THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues

More information

7/9/2013 PRINCIPLES OF DRUG DEVELOPMENT. Charles Flexner, MD Johns Hopkins University

7/9/2013 PRINCIPLES OF DRUG DEVELOPMENT. Charles Flexner, MD Johns Hopkins University PRINCIPLES OF DRUG Charles Flexner, MD Johns Hopkins University Dr. Flexner is disclosing the following potential conflicts as required by the University: Research grants and contracts: NIH, GSK, Merck,

More information

Breast Cancer Drug Discoveries: What the Future Holds

Breast Cancer Drug Discoveries: What the Future Holds Brochure More information from http://www.researchandmarkets.com/reports/679630/ Breast Cancer Drug Discoveries: What the Future Holds Description: In 2010, almost 50% of breast cancer sales were due to

More information

Cancer Drugs Data, Analysis and Forecasts to 2023

Cancer Drugs Data, Analysis and Forecasts to 2023 Cancer Drugs Data, Analysis and Forecasts to 2023 Pharmaceutical, Commercial & Strategic Developments in the Global Cancer Drugs Market to 2023 GMRData.com 1. Executive Summary 1.1. Cancer Drugs Market

More information

Sales Force Effectiveness in Pharmaceuticals

Sales Force Effectiveness in Pharmaceuticals Sales Force Effectiveness in Pharmaceuticals Targeted Sales Models such as Enhanced Key Account Management (KAM) and Closed-Loop Marketing (CLM) Strategies Drives Sales Force Efficiency GBI Research Report

More information

Pharma 2020: The vision Which path will you take?*

Pharma 2020: The vision Which path will you take?* Pharmaceuticals Pharma 2020: The vision Which path will you take?* *connectedthinking pwc Pharma 2020: The vision # Table of contents Introduction 1 A growth market 2 Emerging opportunities 3 Compound

More information

IMI2: Goals and main changes versus IMI (1)

IMI2: Goals and main changes versus IMI (1) IMI2: Goals and main changes versus IMI (1) Elisabetta Vaudano 20150116 Marseille IMI Europe s partnership for health > 5 bn 2.5 bn Partnership 2008-2024 2.5 bn IMI key concepts Focus on unmet needs Non-competitive

More information

Key Drivers of Biotechnology Clusters. Prof Phil Cooke, Centre for Advanced Studies, Cardiff University, Wales, UK

Key Drivers of Biotechnology Clusters. Prof Phil Cooke, Centre for Advanced Studies, Cardiff University, Wales, UK Key Drivers of Biotechnology Clusters Prof Phil Cooke, Centre for Advanced Studies, Cardiff University, Wales, UK Biosciences KVC Exploration Knowledge ICT Fundamental Post-Genomic, Proteomic, Molecunomic

More information

Press Conference Paris, 29 March 2012

Press Conference Paris, 29 March 2012 Does the global pharma- ceutical industry need a new business model? Ludovic Subran, Chief Economist Yann Lacroix, Sector Research Manager Marc Livinec, Sector Analyst Press Conference Paris, 29 March

More information

Critical Path Institute

Critical Path Institute Critical Path Institute Accelerating drug development for Alzheimer s Disease through regulatory science Martha A. Brumfield, PhD President and CEO Accelerating the Path to a Healthier World 1 Critical

More information

Clinical Research Is it a New Paradigm?

Clinical Research Is it a New Paradigm? Clinical Research Is it a New Paradigm? Krathish Bopanna PhD, PhD, DSc Chief Technology Officer Manipal Acunova Bangalore Overview of the Presentation Healthcare Players Drug Development Process Clinical

More information

State of Diabetes-Related Trials in the ClinicalTrials.gov Dataset

State of Diabetes-Related Trials in the ClinicalTrials.gov Dataset State of Diabetes-Related Trials in the ClinicalTrials.gov Dataset Jennifer B. Green, MD 1,2,4 ; Wanda Lakey, MD 1,2 ; Karen Barnard, MBBCh, MPH 1,2 ; Bryan Batch, MD 1,2 ; M Angelyn Bethel, MD 1,3 ; Karen

More information

TABLE OF COMMITMENTS

TABLE OF COMMITMENTS Reaching Goals On, a range of public and private partners are announcing a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by in support

More information

Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap

Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap Quo vadis Pharmaceutical Industry? New strategies to overcome the innovation gap Jochen Maas Stuttgart, May 2014 Quo vadis Pharmaceutical Industry? R&D in the pharmaceutical industry - still a valid model?

More information

Implication of China 2012 NEDL. Presented by: Li Xingwei Yong Hueyling

Implication of China 2012 NEDL. Presented by: Li Xingwei Yong Hueyling Implication of China 2012 NEDL to MNC pharma players Presented by: Li Xingwei Yong Hueyling Content Brief introduction of China NEDL policy China hospital system & MNCs Business Focus Influence of 2012

More information

In the largest and perhaps the most ambitious collaborative

In the largest and perhaps the most ambitious collaborative FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated

More information

Global Pharmaceutical Trade and Contribution of India

Global Pharmaceutical Trade and Contribution of India Global Pharmaceutical Trade and Contribution of India TPR Rau. B. S 1 and Dr. Appaji P. V 2 Abstract: Trends in global pharmaceutical market in terms of sale, product category, product, regions and countries

More information

The Future of R&D Outsourcing

The Future of R&D Outsourcing OUTSOURCING The Future of R&D Outsourcing Investigating development hurdles, key challenges & strategies to optimize CRO relationships By Alison Sahoo Alison Sahoo Alison Sahoo is a pharmaceutical industry

More information

Current Situation of the Pharmaceutical Industry in Puerto Rico

Current Situation of the Pharmaceutical Industry in Puerto Rico The Economic Perspective of Pharmacy: Between Jobs & Costs Panel: What does a Sound Economic Scenario and Cost-Effective Market mean to you? Current Situation of the Pharmaceutical Industry in Puerto Rico

More information

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality

6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality 6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors

More information

Corporate vs non-corporate Venture Capital. Innovation Patient Benefit Superior Returns. May 28, 2016 Ghent, May 26, NVF Freiburg v1

Corporate vs non-corporate Venture Capital. Innovation Patient Benefit Superior Returns. May 28, 2016 Ghent, May 26, NVF Freiburg v1 Corporate vs non-corporate Venture Capital May 28, 2016 Ghent, May 26, 2016 Innovation Patient Benefit Superior Returns NVF Freiburg 4-2016 v1 Definition In essence, it is best to think of CVC as a subset

More information

Rx-360 An International Pharmaceutical Supply Chain Consortium

Rx-360 An International Pharmaceutical Supply Chain Consortium Rx-360 An International Pharmaceutical Supply Chain Consortium Overview Rx-360 and the Audit Sharing Program September 2011 Rx-360 Members (Continuously updated list at www.rx-360.org) Manufacturers (24)

More information

Opportunities for Pharmaceutical Manufacturers in GCC/ MENA

Opportunities for Pharmaceutical Manufacturers in GCC/ MENA 11 April, 2011 Opportunities for Pharmaceutical Manufacturers in GCC/ MENA Dr. Anil Khurana Lead Director, PRTM Middle East Management Consultants Where Innovation Operates Opportunities for Pharmaceutical

More information

2010 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK

2010 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK 2010 CMR INTERNATIONAL PHARMACEUTICAL R&D FACTBOOK June 2010 CMR OVERVIEW CMR International, a Thomson Reuters business, is the world leader in global pharmaceutical R&D performance measurement. For close

More information

Pharmaceuticals Industry Opportunities and Challenges in current market. Nitin Parekh Chief Financial Officer Cadila Healthcare Ltd.

Pharmaceuticals Industry Opportunities and Challenges in current market. Nitin Parekh Chief Financial Officer Cadila Healthcare Ltd. Pharmaceuticals Industry Opportunities and Challenges in current market Nitin Parekh Chief Financial Officer Cadila Healthcare Ltd., Ahmedabad 15 th September, 2009 Global Pharma Industry An Overview Pharma

More information

CRAMS INDIA : OVERVIEW & OUTLOOK. June 2011

CRAMS INDIA : OVERVIEW & OUTLOOK. June 2011 CRAMS INDIA : OVERVIEW & OUTLOOK June 211 ICRA Limited CRAMS INDIA June 211 Agenda: CRAMS Overview & Outlook Description Slide Global Growth Drivers 3-6 Market Dynamics 7 Outsourcing Trends 8 Contract

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch

Pharmaceutical Products Liability. Michael C. Dubin Stephen Knobloch Pharmaceutical Products Liability Michael C. Dubin Stephen Knobloch Objectives Objective 1 Get Actuaries Thinking About Adding Value to New Areas Objective 2 Provide example using pharmaceutical industry

More information

Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Study Context. Study Context. Briefing Overview. Charge to Committee.

Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Study Context. Study Context. Briefing Overview. Charge to Committee. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk IOM Committee on Responsible Sharing of Clinical Trial Data Study Context Responsible clinical trial data sharing is in the public interest

More information

Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan

Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan Comparison of the Non-patent Drug Exclusivities Available in the United States, Canada, Europe and Japan The International Economic Forum of the Americas Serge Lapointe, Ph.D. Partner, Patent Agent June

More information

Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. IOM Committee on Responsible Sharing of Clinical Trial Data

Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. IOM Committee on Responsible Sharing of Clinical Trial Data Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk IOM Committee on Responsible Sharing of Clinical Trial Data Study Context Responsible clinical trial data sharing is in the public interest

More information

Media information. An inspector calls How should manufacturers prepare for tougher inspections? Richard Bonner, European QP Association, advises

Media information. An inspector calls How should manufacturers prepare for tougher inspections? Richard Bonner, European QP Association, advises 28.49 44.49 $58.99 2014 Vol. 2 An inspector calls How should manufacturers prepare for tougher inspections? Richard Bonner, European QP Association, advises Special supplement: Outsourcing & product development

More information

Behavioral Context Patient Involvement

Behavioral Context Patient Involvement 1 Behavioral Context Patient Involvement Preliminary Findings 1,00 0,80 0,60 0,40 0,20 0,00-0,20-0,40-0,60-0,80-1,00 very easy to get somewhat easy to get somewhat difficult to get Accurate Health Information

More information

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization

Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Commercial Insight: Cytotoxic Therapies Market Growth Will Slow Due To Increasing Genericization Report summary In-depth analysis of the current and future cytotoxic therapies market across the US, 5EU

More information

PRESCRIPTION MEDICINES: COSTS IN CONTEXT

PRESCRIPTION MEDICINES: COSTS IN CONTEXT PRESCRIPTION MEDICINES: COSTS IN CONTEXT 2015 Since 2000, biopharmaceutical companies have brought MORE THAN 500 NEW TREATMENTS AND CURES to U.S. patients In the last 100 years, medicines have helped raise

More information

Stakeholder Innovation in Novo Nordisk - DAWN, a case study

Stakeholder Innovation in Novo Nordisk - DAWN, a case study Stakeholder Innovation in Novo Nordisk - DAWN, a case study Soren E. Skovlund Senior Adviser, Manager Stakeholder Relations Novo Nordisk Outline Novo Nordisk The global DAWN (Diabetes Attitudes, Wishes

More information

Figure 1 Selection algorithm for Canadian Pediatric Clinical Trials 2005 2009... 7. Table I Primary Sponsor of Interventional Clinical Trials...

Figure 1 Selection algorithm for Canadian Pediatric Clinical Trials 2005 2009... 7. Table I Primary Sponsor of Interventional Clinical Trials... Canadian Pediatric Clinical Trials Activity 2005 2009 Report completed August 2010 Anne Junker, MD Director, Mother Infant Child Youth Research Network (MICYRN) Réseau de Recherche en Santé des Enfants

More information

Problems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability

Problems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability University of Pennsylvania ScholarlyCommons Master of Science in Organizational Dynamics Theses Organizational Dynamics Programs 5-4-2010 Problems Facing the Pharmaceutical Industry and Approaches to Ensure

More information

The Hong Kong Association of The Pharmaceutical Industry

The Hong Kong Association of The Pharmaceutical Industry The Hong Kong Association of The Pharmaceutical Industry UNIT A, 20/F., TIMES MEDIA CENTRE, FAX: (852) 2865 6283 WEBSITE: www. hkapi.hk Position Paper on the Pharmacy and Poisons (Amendment) Bill 2014

More information

Electronic Health Records for Clinical Research. EHR Compliant to Clinical Trial Requirements. Oct 2009 1. Disclaimer

Electronic Health Records for Clinical Research. EHR Compliant to Clinical Trial Requirements. Oct 2009 1. Disclaimer Electronic Health Records for Clinical EHR Compliant to Clinical Trial Requirements Mathias Poensgen EHRCR project / Aris Global Oct 2009 1 Disclaimer The views and opinions expressed in the following

More information

Role of Competition in the Pharmaceutical Sector and its benefits for Consumers

Role of Competition in the Pharmaceutical Sector and its benefits for Consumers Role of Competition in the Pharmaceutical Sector and its benefits for Consumers Seventh United Nations Conference to review the UN Set on Competition Policy Wednesday 8 th July 2015 Pradeep S Mehta CUTS

More information

As featured in. Orphan disease specialists find home with Big Pharma.

As featured in. Orphan disease specialists find home with Big Pharma. Orphan disease specialists find home with Big Pharma. By Maura Musciacco Senior Analyst January 2013 Tumbling over the patent cliff, many big pharma companies are being forced to find new strategies for

More information

CAN-SPAM Act Rulemaking, Project No. R411008

CAN-SPAM Act Rulemaking, Project No. R411008 1301 K Street NW Suite 900 East Tower Washington DC 20005-3317 Telephone 202 230 5619 Facsimile 202 230 5300 June 27, 2005 By Hand Federal Trade Commission Office of the Secretary, Room H-159 600 Pennsylvania

More information

Company Name Super Sector Sector Segment

Company Name Super Sector Sector Segment A Menarini Abbott Australasia Life Sciences /Diversified AbbVie Actavis Bio-Technology Actelion Agilent Technologies Alere Life Sciences & Alexion /Diversified Life Sciences Allergan Life Sciences /Diversified

More information

Curriculum Vitae of Luca Gianni

Curriculum Vitae of Luca Gianni Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities

More information

ehealthinsight Series: Online Patient Recruitment Strategies

ehealthinsight Series: Online Patient Recruitment Strategies A Datamonitor report ehealthinsight Series: Online Patient Recruitment Strategies Published: May-08 Product Code: Providing you with: Overview of benefits and drawbacks of online Analysis of online patient

More information

Chemotherapy and Advances in Clinical Trials Mark Agulnik, MD Associate Professor in Medicine Hematology / Oncology

Chemotherapy and Advances in Clinical Trials Mark Agulnik, MD Associate Professor in Medicine Hematology / Oncology Chemotherapy and Advances in Clinical Trials Mark Agulnik, MD Associate Professor in Medicine Hematology / Oncology M-Agulnik@northwestern.edu Sarcomas Sarcomas constitute a heterogeneous group of rare

More information

Emerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator

Emerging Clinical Sites: India and China. Patrycja Doba, Clinical Research Coordinator Emerging Clinical Sites: India and China Patrycja Doba, Clinical Research Coordinator Overview 1. Outsourcing trends in Pharmaceutical Industry 2. Reasons for outsourcing 3. The most outsourced activity

More information

Six Sigma strategy applied to the pharmaceutical industry how customers benefit.

Six Sigma strategy applied to the pharmaceutical industry how customers benefit. Six Sigma strategy applied to the pharmaceutical industry - how customer benefit MBA Thesis 2009 School of Management Blekinge Institute of Technology Six Sigma strategy applied to the pharmaceutical industry

More information

11. Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity

11. Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity M1407 - GUGLER TEXT.qxd 7/5/08 11:58 Page 262 Gary GARY'S G4:Users:Gary:Public:Gary's Jobs: 11. Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity Henry Grabowski and

More information

Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography ( )

Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography ( ) Brochure More information from http://www.researchandmarkets.com/reports/3784773/ Europe Kidney Cancer Therapeutics & Diagnostics Market - Segmented by type of cancer and geography (2016-2021) Description:

More information

Canadian Generic Pharmaceutical Association (CGPA)

Canadian Generic Pharmaceutical Association (CGPA) Canadian Generic Pharmaceutical Association (CGPA) October 2004 Generic Drugs. Same Quality. Lower Price. Topics Generic pharmaceuticals Canada s generic pharmaceutical Industry Drug costs in Canada Generic

More information

Biometrics: Clinical Trials and Beyond

Biometrics: Clinical Trials and Beyond Biometrics: Clinical Trials and Beyond Statistics, Programming, and Data Management in Research, Development, and Regulatory Submissions. For all, Not Just Statisticians! Keynote Presentations Sue-Jane

More information

Advancing research: a physician s guide to clinical trials

Advancing research: a physician s guide to clinical trials Advancing research: a physician s guide to clinical trials Recruiting and retaining trial participants is one of the greatest obstacles to developing the next generation of Alzheimer s treatments Alzheimer

More information

Access to Medicines/ section 1

Access to Medicines/ section 1 4 Access to Medicines/ section 1 - Access to Medicines strategies: Providing long term rewards for pharmaceutical innovation MATERIAL, ENVIRONMENTAL, SOCIAL AND GOVERNANCE ISSUES DRIVE THE ALLIANZGI ESG

More information

Canadian Clinical Trial Summit. Break-out Sessions Cost Structure L. Bennett & Dr. S. Choudhri

Canadian Clinical Trial Summit. Break-out Sessions Cost Structure L. Bennett & Dr. S. Choudhri Canadian Clinical Trial Summit Break-out Sessions Cost Structure L. Bennett & Dr. S. Choudhri Agenda Why do trials matter? Site level experience Cost drivers & concurrent financial pressures Impact on

More information

Committed to innovation and growth

Committed to innovation and growth Committed to innovation and growth Alan Hippe, CFO Roche Group London, September 2012 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by

More information

Greater Toronto Area Value Proposition for Life Science Businesses. Your ideal destination for international expansion

Greater Toronto Area Value Proposition for Life Science Businesses. Your ideal destination for international expansion Greater Toronto Area Value Proposition for Life Science Businesses Your ideal destination for international expansion Life Sciences Sector: Ontario One of North America s largest biomedical sectors. Over

More information

The Role Of Industry in the Australian Clinical Trials Sector

The Role Of Industry in the Australian Clinical Trials Sector Mitch Kirkman, Development QA Manager Australian Clinical Trials Alliance Symposium 09 October 2015 CORP0270 September 2015 Global Clinical Development Local Clinical Trials Australian Medical Research

More information

Incurred Sample Reanalysis : EBF s Perspective and Experience

Incurred Sample Reanalysis : EBF s Perspective and Experience European Bioanalysis Forum Incurred Sample Reanalysis : s Perspective and Experience steering committee : Philip Timmerman (Johnson & Johnson), presenter Berthold Lausecker (F. Hoffmann-La Roche ) Margarete

More information

Will there be a new golden age of drug discovery?

Will there be a new golden age of drug discovery? Will there be a new golden age of drug discovery? RSC-SCI Advances in Synthesis and Medicinal Chemistry Welwyn Garden City, May 1, 2012 David Brown PhD, FRSC Alchemy Biomedical Consulting Ltd, Cambridge,

More information

H E A L T H C A R E. Market trends, leading players and forecasts. Report Price Publication date. 1995/ 2880/$3835 June 2009

H E A L T H C A R E. Market trends, leading players and forecasts. Report Price Publication date. 1995/ 2880/$3835 June 2009 F o r a c l e a r e r m a r k e t p e r s p e c t i v e The US Pharmaceutical Market Outlook to 2014 Market trends, leading players and forecasts Report Price Publication date 1995/ 2880/$3835 June 2009

More information

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore

Selling an Idea. Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Selling an Idea Dr. Mark McHale Chief Scientific Officer ASLAN Pharmaceuticals Singapore Seminar Format XXXX Know Your Stuff Andy Murray The Beetles Read everything in your field Keep up to date Be dedicated

More information